Key papers in Infectious Diseases
Pofolia’s corpus holds 64 papers from the Infectious Diseases subfield (1998–2020). The list below starts with the most cited.
Most cited
Ranked by citation count. Because citations accumulate over time, this list naturally leans towards work published a few years ago; for where the field is now, see “recently added”.
Clinical Characteristics of Coronavirus Disease 2019 in China
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 704.52 · 31,181 citations
A study of 1099 COVID-19 patients in China found a 6.1% rate of severe outcomes (ICU admission, mechanical ventilation, or death), with fever and cough being the most common symptoms, though many patients presented without fever and some had no initial radiologic abnormalities.
A Novel Coronavirus from Patients with Pneumonia in China, 2019
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 668.76 · 30,418 citations
A previously unknown betacoronavirus, named 2019-nCoV, was identified in patients with pneumonia linked to a market in Wuhan, China.
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Nature · 2020 · Q1 · SJR 19.00 · FWCI 509.38 · 23,375 citations · Open access
A new coronavirus, 2019-nCoV, identified from an outbreak of acute respiratory syndrome in Wuhan, China, shares 96% whole-genome identity with a bat coronavirus and 79.6% sequence identity with SARS-CoV.
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China
JAMA · 2020 · Q1 · SJR 5.00 · FWCI 479.59 · 21,199 citations · Open access
In a Wuhan hospital, 41% of 138 hospitalized pneumonia patients likely contracted 2019-nCoV from the hospital, with 26% requiring ICU care and an overall mortality rate of 4.3%.
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
DSPACE System - Metalibrary (University of the Coast) · 2020 · 19,310 citations
The COVID-19 pandemic in 2020 disrupted global certainties, highlighting the virus's rapid contagion and high lethality in individuals with pre-existing conditions.
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China
JAMA · 2020 · Q1 · SJR 5.00 · FWCI 399.88 · 18,027 citations · Open access
This viewpoint summarizes key epidemiologic and clinical findings from COVID-19 cases in mainland China reported up to February 11, 2020. It also analyzes case trends in relation to government control measures.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 297.38 · 15,595 citations
The BNT162b2 mRNA vaccine candidate demonstrated 95% efficacy in preventing Covid-19 after two doses, with a similar safety profile to other viral vaccines.
A new coronavirus associated with human respiratory disease in China
Nature · 2020 · Q1 · SJR 19.00 · FWCI 279.42 · 12,935 citations · Open access
Researchers identified a novel RNA virus, designated 'WH-Human 1' coronavirus, from a patient with severe respiratory illness in Wuhan, China.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 197.70 · 10,782 citations
The mRNA-1273 vaccine demonstrated 94.1% efficacy in preventing symptomatic COVID-19 illness, including severe disease, in a large-scale Phase 3 trial.
Dexamethasone in Hospitalized Patients with Covid-19
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 205.01 · 10,118 citations
Dexamethasone significantly reduced 28-day mortality by 17% (rate ratio 0.83) in hospitalized COVID-19 patients. The benefit was most pronounced in patients requiring mechanical ventilation or oxygen support.
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
JAMA · 2020 · Q1 · SJR 5.00 · FWCI 219.85 · 9,899 citations
A case series of 5700 hospitalized COVID-19 patients in NYC revealed a median age of 63, with hypertension (56.6%), obesity (41.7%), and diabetes (33.8%) as common comorbidities. Overall, 21% died during hospitalization, and 12.2% required mechanical ventilation.
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Science · 2020 · Q1 · SJR 10.00 · FWCI 210.96 · 9,794 citations · Open access
Researchers determined the 3.5-angstrom cryo-EM structure of the 2019-nCoV spike protein in its prefusion state, revealing a predominant conformation with one receptor-binding domain accessible for interaction.
Down-Regulation of Na<sup>+</sup>/K<sup>+</sup>ATPase Activity by Human Parvovirus B19 Capsid Protein VP1
Cellular Physiology and Biochemistry · 2013 · Q3 · FWCI 140.35 · 8,699 citations · Open access
Human parvovirus B19's capsid protein VP1 significantly inhibits the host cell's Na+/K+-ATPase activity, a key ion pump, by producing lysophosphatidylcholine.
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Eurosurveillance · 2020 · Q1 · SJR 2.00 · FWCI 178.51 · 8,190 citations · Open access
A validated real-time RT-PCR diagnostic workflow for the novel 2019-nCoV has been developed and deployed, capable of detecting the virus and distinguishing it from SARS-CoV without requiring live virus samples.
Dexamethasone in Hospitalized Patients with Covid-19.
DiRROS repository (University of Maribor) · 2020 · FWCI 183.55 · 8,046 citations
Dexamethasone significantly reduced 28-day mortality by 17% in hospitalized COVID-19 patients requiring respiratory support, but showed no benefit for those not needing oxygen.
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
Nature Microbiology · 2020 · Q1 · SJR 7.00 · FWCI 169.04 · 7,756 citations · Open access
The Coronaviridae Study Group (CSG) has officially classified the novel coronavirus causing the COVID-19 outbreak as SARS-CoV-2, recognizing it as a distinct species within the Severe acute respiratory syndrome-related coronavirus group.
Remdesivir for the Treatment of Covid-19 — Final Report
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 164.45 · 7,738 citations
Intravenous remdesivir significantly shortened the time to recovery for hospitalized COVID-19 patients with lower respiratory tract infection, reducing it from 15 days to 10 days compared to placebo.
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Cell Research · 2020 · Q1 · SJR 6.00 · FWCI 167.70 · 7,386 citations · Open access
Remdesivir and chloroquine have demonstrated in vitro efficacy against the novel coronavirus (2019-nCoV), suggesting potential therapeutic options.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Internet Archive (Internet Archive) · 2020 · 7,341 citations
The mRNA-1273 vaccine demonstrated 94.1% efficacy in preventing symptomatic COVID-19 after two doses in a large Phase 3 trial.
First Case of 2019 Novel Coronavirus in the United States
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 147.94 · 6,399 citations
The first confirmed case of 2019-nCoV infection in the United States is reported, detailing its identification, diagnosis, and clinical progression from mild symptoms to pneumonia.
Recently added
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 197.70 · 10,782 citations
The mRNA-1273 vaccine demonstrated 94.1% efficacy in preventing symptomatic COVID-19 illness, including severe disease, in a large-scale Phase 3 trial.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Internet Archive (Internet Archive) · 2020 · 7,341 citations
The mRNA-1273 vaccine demonstrated 94.1% efficacy in preventing symptomatic COVID-19 after two doses in a large Phase 3 trial.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 297.38 · 15,595 citations
The BNT162b2 mRNA vaccine candidate demonstrated 95% efficacy in preventing Covid-19 after two doses, with a similar safety profile to other viral vaccines.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
The Lancet · 2020 · FWCI 106.62 · 5,017 citations · Open access
The ChAdOx1 nCoV-19 vaccine showed 62.1% efficacy with two standard doses and 90.0% efficacy with a low-then-standard dose regimen against symptomatic COVID-19 in an interim analysis of four trials.
Characteristics of SARS-CoV-2 and COVID-19
Nature Reviews Microbiology · 2020 · Q1 · SJR 18.00 · FWCI 95.81 · 5,467 citations · Open access
This review details the virology, clinical features, and origins of SARS-CoV-2 and COVID-19, highlighting key differences from other coronaviruses.
Add this field to your daily feed
Pick your interests and new work in your area arrives every day, summarised. Full summaries live in the app.
Open the app